Melanoma drug Vemurafenib may increase risk of squamous cell carcinoma

According to a study published in the New England Journal of Medicine, Vemurafenib (Zelboraf) speeds the growth of squamous cell carcinoma. HealthDay explained that “roughly one-quarter of patients who take the medication develop a troublesome side effect: secondary skin cancers called squamous cell carcinomas.”

Advertisements

We want to know what you think. Leave a Reply.

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s